Recent genetic studies identified the heterozygous mutations in GBA1 as a strong risk for sporadic Parkinson’s disease (PD) and dementia with Lewy bodies, whose pathological hallmark is the disease-specific inclusion bodies, composed of α-synuclein (asyn) called Lewy bodies [3–5]. Here, GBA1 is linked to Parkinson disease.